Dystrotelin inhibitors are a class of chemical compounds that specifically target and inhibit dystrotelin, a protein believed to be involved in cytoskeletal organization and cellular structural integrity. Dystrotelin is associated with actin-binding activities, contributing to the stabilization and maintenance of the cytoskeleton. This protein is important for cellular processes such as migration, adhesion, and the regulation of cell shape, particularly in muscle cells and other highly structured cell types. Inhibitors of dystrotelin function by interfering with its binding to actin or by altering its conformational states, thereby disrupting its role in cytoskeletal assembly and maintenance.
Dystrotelin inhibitors may include small molecules or peptides that interact directly with the actin-binding domains of the protein. These compounds are often designed to mimic the natural substrates or interaction partners of dystrotelin, allowing them to compete with these molecules at key binding sites. By inhibiting dystrotelin's interaction with the actin cytoskeleton, these inhibitors can alter cellular mechanics and provide insights into the protein's role in maintaining structural integrity under various conditions. The disruption of dystrotelin function by these inhibitors serves as a valuable tool in research on cytoskeletal dynamics, helping to uncover the molecular mechanisms by which cells regulate their shape, motility, and internal organization. Additionally, the study of dystrotelin inhibitors allows researchers to explore the broader impact of actin-binding proteins in cellular architecture and function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Sirolimus binds to the mTOR complex and inhibits its activity, which can result in the downregulation of protein synthesis, including possibly "dystrotelin". | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which could downregulate AKT/mTOR signaling, potentially leading to reduced protein synthesis including "dystrotelin". | ||||||
WYE-125132 | 1144068-46-1 | sc-364651 sc-364651A | 10 mg 50 mg | $510.00 $1536.00 | ||
WYE-125132 is a potent inhibitor of mTOR, which could decrease the expression of proteins regulated by this pathway. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor, which could lead to cell cycle arrest and potentially downregulate proteins like "dystrotelin". | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Olaparib, a PARP inhibitor, may influence various cellular processes including the expression of certain proteins. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Nutlin-3 disrupts the interaction between p53 and MDM2, which could lead to changes in gene expression profiles. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is an inhibitor of the TGF-β receptor, affecting downstream signaling and possibly altering protein expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, potentially affecting transcription factors regulated by JNK and altering protein expression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor, which might lead to the downregulation of ERK signaling and affect gene expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is another MEK inhibitor, known to block ERK phosphorylation and thus could influence protein expression. | ||||||